Targeting the Fas/Fas ligand pathway in cancer

Author： O’Brien Darren I   Nally Ken   Kelly Raymond G   O’Connor Terrence M   Shanahan Fergus   O’Connell Joe  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.9, Iss.5, 2005-10, pp. : 1031-1044

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fas ligand: a potential target for therapeutic induction of apoptosis and enhancing immunotherapy in cancer

By O'Connell J.  

Expert Opinion on Therapeutic Targets, Vol. 3, Iss. 4, 1999-12 ,pp. : 601-611

Informa Healthcare

Access to resources Recommend Favorite

The Use of Fas Ligand, TRAIL and Bax in Gene Therapy of Prostate Cancer

By  

Current Gene Therapy, Vol. 1, Iss. 1, 2001-05 ,pp. : 123-136

Bentham Science Publishers

Access to resources Recommend Favorite

Considering Fas ligand as a target for therapy

By Linkermann Andreas   Qian Jing   Lettau Marcus   Kabelitz Dieter   Janssen Ottmar  

Expert Opinion on Therapeutic Targets, Vol. 9, Iss. 1, 2005-02 ,pp. : 119-134

Informa Healthcare

Access to resources Recommend Favorite

Functional Expression of Fas and Fas Ligand on Human Colonic Intraepithelial T Lymphocytes

By Hongo T   Morimoto Y   Iwagaki H   Kobashi K   Yoshii M   Urushihara N   Hizuta A   Tanaka N  

The Journal of International Medical Research, Vol. 28, Iss. 3, 2000-05 ,pp. : 132-142

Field House Publishing

Access to resources Recommend Favorite

Targeting Fas/FasL signaling, a new strategy for maintaining bone health

By Imai Yuuki   Kouzmenko Alexander   Kato Shigeaki  

Expert Opinion on Therapeutic Targets, Vol. 15, Iss. 10, 2011-10 ,pp. : 1143-1145

Informa Healthcare

Access to resources Recommend Favorite